<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Stress response gene ATF3 is one of the p53 target genes and has a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor role in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, the biological role of p53-ATF3 pathway is not well understood </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0011420'>Death</z:hpo> receptor 5 (DR5) is a <z:hpo ids='HP_0011420'>death</z:hpo> domain-containing transmembrane receptor that triggers cell <z:hpo ids='HP_0011420'>death</z:hpo> upon binding to its ligand TRAIL (<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-related <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-inducing ligand), and a combination of TRAIL and agents that increase the expression of DR5 is expected as a novel anticancer therapy </plain></SENT>
<SENT sid="3" pm="."><plain>In this report, we demonstrate that ATF3 is required for efficient DR5 induction upon DNA damage by <z:chebi fb="0" ids="27656">camptothecin</z:chebi> (<z:chebi fb="9" ids="27656">CPT</z:chebi>) in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells </plain></SENT>
<SENT sid="4" pm="."><plain>In the absence of ATF3, induction of DR5 <z:chebi fb="5" ids="33699">messenger RNA</z:chebi> and protein is remarkably abrogated, and this is associated with reduced cell <z:hpo ids='HP_0011420'>death</z:hpo> by TRAIL and <z:chebi fb="9" ids="27656">CPT</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>By contrast, exogenous expression of ATF3 causes more rapid and elevated expression of DR5, resulting in enhanced sensitivity to apoptotic cell <z:hpo ids='HP_0011420'>death</z:hpo> by TRAIL/<z:chebi fb="9" ids="27656">CPT</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Reporter assay and DNA affinity precipitation assay demonstrate that at least three ATF/CRE motifs at the proximal promoter of the human DR5 gene are involved in the activation of DNA damage-induced DR5 gene transcription </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, ATF3 is shown to interact with p53 to form a complex on the DR5 gene by Re-chromatin immunoprecipitation assay </plain></SENT>
<SENT sid="8" pm="."><plain>Taken together, our results provide a novel insight into the role of ATF3 as an essential co-transcription factor for p53 upon DNA damage, and this may represent a useful biomarker for TRAIL-based anticancer therapy </plain></SENT>
</text></document>